Low Dose Naltrexone & Depression

Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome.

 

Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.

 

Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.

 

 A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence.

 

 Update on Pharmacotherapy in Psychodermatological Disorders.

 

 Low-dose naltrexone for disease prevention and quality of life.

 

Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.

 

Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1].

 

Antagonism of morphine-induced respiratory depression with nalmefene.

 

Threshold differences for naloxone and naltrexone in the hypothalamus and midbrain using fixed ratio brain self-stimulation in rats.

 

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

 

Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.

 

A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.

 

Hippocampal kindling-induced after-discharge and behavioural depression: immediate and long-term attenuation by opiate antagonists.

 

Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.

 

Effects of morphine and narcotic antagonists on avoidance behavior of the squirrel monkey.